Developmental exposure to the organochlorine pesticide dieldrin causes male-specific exacerbation of α-synuclein-preformed fibril-induced toxicity and motor deficits.
Animals
Dieldrin
/ toxicity
Dopamine
/ metabolism
Female
Male
Mice, Inbred C57BL
Motor Activity
/ drug effects
Parkinsonian Disorders
/ chemically induced
Pesticides
/ toxicity
Protein Aggregation, Pathological
/ chemically induced
Sex Factors
Substantia Nigra
/ metabolism
alpha-Synuclein
/ administration & dosage
Neuroinflammation
Neurotoxicity
Parkinson's
Pesticide
Sex differences
Synuclein
Journal
Neurobiology of disease
ISSN: 1095-953X
Titre abrégé: Neurobiol Dis
Pays: United States
ID NLM: 9500169
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
05
02
2020
revised:
22
04
2020
accepted:
13
05
2020
pubmed:
19
5
2020
medline:
15
7
2021
entrez:
19
5
2020
Statut:
ppublish
Résumé
Human and animal studies have shown that exposure to the organochlorine pesticide dieldrin is associated with increased risk of Parkinson's disease (PD). Previous work showed that developmental dieldrin exposure increased neuronal susceptibility to MPTP toxicity in male C57BL/6 mice, possibly via changes in dopamine (DA) packaging and turnover. However, the relevance of the MPTP model to PD pathophysiology has been questioned. We therefore studied dieldrin-induced neurotoxicity in the α-synuclein (α-syn)-preformed fibril (PFF) model, which better reflects the α-syn pathology and toxicity observed in PD pathogenesis. Specifically, we used a "two-hit" model to determine whether developmental dieldrin exposure increases susceptibility to α-syn PFF-induced synucleinopathy. Dams were fed either dieldrin (0.3 mg/kg, every 3-4 days) or vehicle corn oil starting 1 month prior to breeding and continuing through weaning of pups at postnatal day 22. At 12 weeks of age, male and female offspring received intrastriatal α-syn PFF or control saline injections. Consistent with the male-specific increased susceptibility to MPTP, our results demonstrate that developmental dieldrin exposure exacerbates PFF-induced toxicity in male mice only. Specifically, in male offspring, dieldrin exacerbated PFF-induced motor deficits on the challenging beam and increased DA turnover in the striatum 6 months after PFF injection. However, male offspring showed neither exacerbation of phosphorylated α-syn aggregation (pSyn) in the substantia nigra (SN) at 1 or 2 months post-PFF injection, nor exacerbation of PFF-induced TH and NeuN loss in the SN 6 months post-PFF injection. Collectively, these data indicate that developmental dieldrin exposure produces a male-specific exacerbation of synucleinopathy-induced behavioral and biochemical deficits. This sex-specific result is consistent with both previous work in the MPTP model, our previously reported sex-specific effects of this exposure paradigm on the male and female epigenome, and the higher prevalence and more severe course of PD in males. The novel two-hit environmental toxicant/PFF exposure paradigm established in this project can be used to explore the mechanisms by which other PD-related exposures alter neuronal vulnerability to synucleinopathy in sporadic PD.
Identifiants
pubmed: 32422283
pii: S0969-9961(20)30222-9
doi: 10.1016/j.nbd.2020.104947
pmc: PMC7343230
mid: NIHMS1598492
pii:
doi:
Substances chimiques
Pesticides
0
alpha-Synuclein
0
Dieldrin
I0246D2ZS0
Dopamine
VTD58H1Z2X
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
104947Subventions
Organisme : NIEHS NIH HHS
ID : R00 ES024570
Pays : United States
Organisme : NIEHS NIH HHS
ID : R21 ES029205
Pays : United States
Organisme : NINDS NIH HHS
ID : R33 NS099416
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Références
Can J Neurol Sci. 1991 Aug;18(3):279-86
pubmed: 1913361
Neurotoxicology. 2012 Oct;33(5):947-71
pubmed: 22627180
J Parkinsons Dis. 2018;8(2):303-322
pubmed: 29400668
J Neurosci. 2009 Jun 24;29(25):8103-13
pubmed: 19553450
J Neurochem. 1998 May;70(5):1973-8
pubmed: 9572281
Anat Rec. 1991 Dec;231(4):482-97
pubmed: 1793176
FASEB J. 2020 Jan;34(1):1679-1694
pubmed: 31914683
Toxicol Lett. 1991 Apr;Suppl:1-206
pubmed: 2014520
Neurosci Lett. 1996 Jun 14;211(1):13-6
pubmed: 8809836
Environ Res. 2001 Jun;86(2):122-7
pubmed: 11437458
J Biol Chem. 2016 Sep 2;291(36):18675-88
pubmed: 27382062
Adv Neurol. 1993;60:600-8
pubmed: 8380528
Science. 2012 Nov 16;338(6109):949-53
pubmed: 23161999
Nat Rev Genet. 2006 Apr;7(4):306-18
pubmed: 16543934
J Neurosci. 2013 Jun 5;33(23):9592-600
pubmed: 23739956
Ann Neurol. 2014 Mar;75(3):351-62
pubmed: 24243558
Neurotoxicology. 2005 Aug;26(4):701-19
pubmed: 16112328
J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):851-7
pubmed: 19246476
Brain. 2013 Aug;136(Pt 8):2419-31
pubmed: 23884810
Front Neuroendocrinol. 2014 Aug;35(3):370-84
pubmed: 24607323
Pharmacol Biochem Behav. 2014 Nov;126:28-35
pubmed: 25242810
J Toxicol Environ Health A. 2000 Feb 25;59(4):229-34
pubmed: 10706031
J Vis Exp. 2019 Jun 2;(148):
pubmed: 31205308
J Neurosci. 2008 Jan 9;28(2):425-33
pubmed: 18184785
Synapse. 1999 Jun 1;32(3):165-76
pubmed: 10340627
PLoS One. 2015 Jun 18;10(6):e0128651
pubmed: 26087293
Ann Neurol. 2006 Aug;60(2):197-203
pubmed: 16802290
J Exp Med. 2012 May 7;209(5):975-86
pubmed: 22508839
Proc Natl Acad Sci U S A. 2014 Jul 8;111(27):9977-82
pubmed: 24979780
J Neurosci. 2005 Feb 23;25(8):2132-7
pubmed: 15728853
Sci Rep. 2015 Sep 18;5:14211
pubmed: 26381815
Int J Epidemiol. 2000 Apr;29(2):323-9
pubmed: 10817132
Am J Epidemiol. 2003 Jun 1;157(11):1015-22
pubmed: 12777365
Epidemiology. 2006 Jan;17(1):8-13
pubmed: 16357589
Neurobiol Aging. 2003 Mar-Apr;24(2):197-211
pubmed: 12498954
Neurobiol Dis. 2015 Oct;82:185-199
pubmed: 26093169
Neurology. 1992 Jul;42(7):1328-35
pubmed: 1620342
Exp Neurol. 1998 Apr;150(2):339-42
pubmed: 9527905
J Neuroinflammation. 2018 May 1;15(1):129
pubmed: 29716614
J Neurosci. 2004 Oct 20;24(42):9434-40
pubmed: 15496679
J Clin Epidemiol. 2002 Jan;55(1):25-31
pubmed: 11781119
Behav Brain Res. 2018 May 2;343:41-49
pubmed: 29407413
J Gend Specif Med. 2000 Sep-Oct;3(6):36-42
pubmed: 11253381
Acta Neurol Scand. 2017 Dec;136(6):570-584
pubmed: 28670681
Parkinsons Dis. 2011 Feb 21;2011:124165
pubmed: 21403896
Nat Immunol. 2011 May;12(5):416-24
pubmed: 21441935
J Neurosci. 1997 Apr 1;17(7):2420-8
pubmed: 9065503
Pharmacol Toxicol. 1996 Jul;79(1):1-14
pubmed: 8841090
Nat Protoc. 2014 Sep;9(9):2135-46
pubmed: 25122523
Exp Neurol. 2002 Nov;178(1):80-90
pubmed: 12460610
Environ Health Perspect. 2001 Mar;109 Suppl 1:113-39
pubmed: 11250811
Toxicol Lett. 1995 Dec;82-83:239-45
pubmed: 8597060
Environ Sci Technol. 2001 May 15;35(10):1989-95
pubmed: 11393978
Neurology. 2000 Nov 14;55(9):1358-63
pubmed: 11087781
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):905-6
pubmed: 17635983
J Chem Neuroanat. 2017 Oct;83-84:82-90
pubmed: 27836486
Redox Biol. 2017 Apr;11:429-437
pubmed: 28068606
Acta Neuropathol. 2003 Dec;106(6):518-26
pubmed: 14513261
Neurobiol Dis. 2012 Sep;47(3):367-77
pubmed: 22659302
Behav Brain Res. 2012 May 1;230(2):309-16
pubmed: 22178078
Neurotoxicology. 2000 Aug;21(4):435-40
pubmed: 11022853
FASEB J. 2006 Aug;20(10):1695-7
pubmed: 16809432
Perspect Dev Neurobiol. 1998;5(2-3):247-59
pubmed: 9777640
Curr Opin Neurol. 2000 Aug;13(4):427-30
pubmed: 10970060
Neurotoxicology. 2011 Aug;32(4):383-91
pubmed: 21402100
Biomed Pharmacother. 1999 Apr;53(3):122-30
pubmed: 10349500
J Neurol Neurosurg Psychiatry. 2004 Apr;75(4):637-9
pubmed: 15026515
Exp Neurol. 2007 Apr;204(2):619-30
pubmed: 17291500
Mol Cell Neurosci. 2011 Mar;46(3):597-606
pubmed: 21193046
Cell Rep. 2016 Sep 20;16(12):3373-3387
pubmed: 27653697
J Neurochem. 2004 Apr;89(1):7-14
pubmed: 15030384
Ann Neurol. 2012 Oct;72(4):517-24
pubmed: 23109146
Neuropeptides. 2008 Aug;42(4):423-34
pubmed: 18533255
Trends Pharmacol Sci. 2008 Jun;29(6):322-9
pubmed: 18453001
Neuroscience. 2003;119(4):945-64
pubmed: 12831855
Eur J Neurosci. 2006 Nov;24(9):2622-30
pubmed: 17100850
Neurobiol Dis. 2017 Sep;105:84-98
pubmed: 28576704
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
J Neurochem. 2001 Feb;76(4):1010-21
pubmed: 11181820
Neuron. 1997 Dec;19(6):1285-96
pubmed: 9427251
Eur J Epidemiol. 2011 Jun;26 Suppl 1:S1-58
pubmed: 21626386
J Pharmacol Exp Ther. 1997 Jan;280(1):439-46
pubmed: 8996226
Toxicol Sci. 2019 Jul 1;170(1):133-143
pubmed: 30907971
Cell Rep. 2015 Mar 3;10(8):1252-60
pubmed: 25732816
Ann Neurol. 1994 Jul;36(1):100-3
pubmed: 7517654
Toxicol Sci. 2019 Jun 1;169(2):593-607
pubmed: 30859219
Neurology. 1990 Oct;40(10 Suppl 3):suppl 17-30; discussion 30-1
pubmed: 2215971
Curr Neurol Neurosci Rep. 2013 Jul;13(7):362
pubmed: 23690026
Neurotoxicology. 2012 Mar;33(2):178-88
pubmed: 22309908
Environ Health Perspect. 2006 Feb;114(2):156-64
pubmed: 16451848
Neurobiol Dis. 2019 Oct;130:104525
pubmed: 31276792
Neuron. 2003 Sep 11;39(6):889-909
pubmed: 12971891
Ann Neurol. 2009 Oct;66(4):494-504
pubmed: 19847896
Parkinsonism Relat Disord. 2010 Jul;16(6):365-9
pubmed: 20471298
Brain. 2013 Apr;136(Pt 4):1128-38
pubmed: 23466394
Exp Neurol. 1998 Apr;150(2):263-71
pubmed: 9527896
J Biol Chem. 2003 Oct 31;278(44):43628-35
pubmed: 12930822
J Vis Exp. 2017 Sep 1;(127):
pubmed: 28892024
Toxicol Sci. 2016 Sep;153(1):79-88
pubmed: 27287315
NPJ Parkinsons Dis. 2015;1:
pubmed: 27148593
Neurology. 2010 Mar 30;74(13):1055-61
pubmed: 20350979
Neuron. 2011 Oct 6;72(1):57-71
pubmed: 21982369
Environ Health Perspect. 2011 Jun;119(6):866-72
pubmed: 21269927
J Neurol Neurosurg Psychiatry. 2007 Aug;78(8):819-24
pubmed: 17098842
J Neurosci. 2007 Jul 25;27(30):8138-48
pubmed: 17652604
Free Radic Biol Med. 2001 Dec 1;31(11):1473-85
pubmed: 11728820
J Neuroinflammation. 2005 Jun 03;2:14
pubmed: 15935098